Evidence map›Paper›PMID 39930224›Full record

ReviewAdvances in experimental medicine and biology2025

Immunogenic Switch of RPE Cells.

Andjela Sekulic, Gerhild Wildner, Christine Skerka, Olaf Strauß

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andjela SekulicExperimental Ophthalmology, Department of Ophthalmology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin Institute of Health, Humboldt-Universität, Berlin, Germany. andjela.sekulic@charite.de.
Gerhild WildnerSection of Immunobiology, Department of Ophthalmology, University Hospital, LMU Munich, Munich, Germany.
Christine SkerkaDepartment of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Hans-Knoell-Institute, Jena, Germany.
Olaf StraußExperimental Ophthalmology, Department of Ophthalmology, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin Institute of Health, Humboldt-Universität, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The barrier function of the retinal pigment epithelium (RPE) secures a highly selective exchange of molecules between the blood stream of the choroid and retina but also maintenance of the immune privilege of the retina. The latter function includes a mechanical barrier through the tight junctions and immune barrier of either membrane bound or secreted immune-suppressive factors in response to increasing inflammatory activities in the outer retina. However, in disease, both physical and immune barriers are compromised to allow accumulation of immune cells in the subretinal space or even to pass across the RPE into the retinal space. The ability of the RPE to secrete immune stimulatory factors such as MCP-1, as a response to the increased inflammation, suggests that disease goes along with an immunogenic switch. We recently found that stressed RPE cells express the transcription factor FoxP3 and its activation leads to secretion of pro-inflammatory factors. Indeed, RPE cells in either mouse models with age-related macular degeneration (AMD) relevance or in retinas from AMD patients, express FoxP3 in the RPE, which was not observed in healthy donors. FoxP3 appears first as a rescue factor for the RPE in the increasing presence of pro-inflammatory proteins such as IL1β or active complement that eventually changes the immunogenic phenotype from anti-inflammatory to pro-inflammatory.

Indexed as

Macular DegenerationRetinal Pigment EpitheliumAnimalsForkhead Transcription FactorsHumansMiceForkhead Transcription FactorsFOXP3 protein, humanAge-related macular degeneration (AMD)AnaphylatoxinsComplement systemFoxP3Immune-activationImmune privilegeImmune-suppressionImmune-switchRetinal pigment epithelium (RPE)Terminal complement system

Identifiers

PMID39930224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.